Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , may offer a promising development for obesity loss . Preliminary clinical investigations have indicated impressive reductions in abdominal tissue, conceivably surpassing existing body composition therapies . However , more assessment is needed to thorough